Condition: Prostate Adenocarcinoma · Castration Sensitive Prostate Cancer · Sponsor: Ontario Clinical Oncology Group (OCOG)
The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-metastatic castrate / hormone sensitive prostate cancer (romCSPC). Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months.
This description comes directly from the study's public registry record.
Lisa Rudd-Scott, RN BScN · 905-527-2299 · ruddl@mcmaster.ca
Daryl Solomon · 905-527-2299 · solomd5@mcmaster.ca
Always discuss trial participation with your own doctor first.
| Juravinski Cancer Centre | Hamilton, Ontario, Canada | Recruiting |
| The Ottawa Hospital Regional Cancer Centre | Ottawa, Ontario, Canada | Not Yet Recruiting |
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06654336